IBRX News & Events

Reports Q1 revenue $44.2M, consensus $43.94M. "We continue to see strong demand for ANKTIVA from both new prescribers and physicians expanding use across multiple eligible patients, including in the maintenance setting," said Richard Adcock, President and CEO of ImmunityBio. "We have also made meaningful progress expanding market access beyond the U.S., with ANKTIVA now commercially available in Saudi Arabia and additional markets anticipated this year. We are entering Q2 with a strong cash position, growing revenues, and a more experienced commercial organization positioned to support continued growth."

ImmunityBio announced that ANKTIVA is now commercially available in Saudi Arabia. Initial patients have been identified for treatment across both approved bladder and lung cancer indications in the Kingdom: In combination with Bacillus Calmette-Guerin for the treatment of adult patients with BCG-unresponsive non-muscle invasive bladder cancer carcinoma in situ, with or without papillary disease; and In combination with an immune checkpoint inhibitor for the treatment of adult patients with metastatic non-small cell lung cancer, as authorized by the Saudi Food and Drug Authority. ANKTIVA is being distributed through ImmunityBio's partnerships with Biopharma and Cigalah Healthcare, leading healthcare distribution companies in the Middle East, with support from the company's wholly owned subsidiary in Saudi Arabia.